DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a poor prognosis that is characterized by excessive mitogenic pathway activation and marked chemoresistance to a broad spectrum of chemotherapeutic drugs. Dual specificity protein phosphatase 1 (DUSP1) is a key negative regulator of mit...
Main Authors: | Fang Liu, A Jesse Gore, Julie L Wilson, Murray Korc |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24409315/pdf/?tool=EBI |
Similar Items
-
Correction: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
by: The Staff
Published: (2014-01-01) -
Correction: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine.
Published: (2014-01-01) -
Expression of Concern: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine.
by: PLOS ONE Editors
Published: (2020-01-01) -
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
by: Amber Blaauboer, et al.
Published: (2020-09-01) -
DUSP1 Blocks autophagy-dependent ferroptosis in pancreatic cancer
by: Yangchun Xie, et al.
Published: (2020-09-01)